O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Inclusion Criteria:

* Patients with glioblastoma multiforme or gliosarcoma
* The patient or legal guardian must be able to comprehend the informed consent form and sign prior to patient enrollment
* Karnofsky performance status at time of study entry must be \>= 70%
* Life expectancy of \>= 3 months
* Patients must agree to undergo repeat clinical neurological examinations and brain magnetic resonance imaging (MRI) with appropriate contrast after every other cycle of chemotherapy
* White blood cell (WBC) \> 3000/ul
* Absolute neutrophil count (ANC) \> 1500/ul
* Platelets \> 100,000/ul
* Hemoglobin \> 10 gm/100ml
* Total and direct bilirubin \< 1.5 times upper limit of laboratory normal
* Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =\< 3 times upper limit of laboratory normal
* Alkaline phosphatase =\< 3 times upper limit of laboratory normal
* Blood urea nitrogen (BUN) \< 1.5 times upper limit of laboratory normal
* Serum creatinine \< 1.5 times upper limit of laboratory normal
* Left ventricular ejection fraction (LVEF) \>= 40%, however, subjects with a LVEF in the range of 40-49% should have cardiology clearance prior to intervention
* MGMT promoter methylation analysis of surgically resected tumor or tumor biopsy must demonstrate an unmethylated or hypomethylated MGMT promoter status

Exclusion Criteria:

* Patients with cardiac insufficiency and a LVEF of \< 40%; history of coronary artery disease or arrhythmia, which has required or requires ongoing treatment
* Patients with active pulmonary infection and/or pulse oximetry \< 90% and a corrected diffusion capacity of the lung for carbon monoxide (DLCO) \< 70% of predicted
* Active systemic infection
* Patients who are human immunodeficiency virus (HIV) positive
* Pregnant or lactating women; a beta-human chorionic gonadotropin (HCG) level will be obtained from women of childbearing potential; fertile men and women should use effective contraception
* Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC) or prior nitrosourea
* Diabetes mellitus
* Bleeding disorder
* Methylated or hypermethylated MGMT promoter status within tumor tissue
* Medical or psychiatric condition which in the opinion of the protocol chairman would compromise the patient's ability to tolerate this protocol
* Prior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted BCNU-wafers